New hope for HIV patients with aggressive lymphoma: early trial launches
NCT ID NCT07649304
First seen Jun 17, 2026 · Last updated Jun 22, 2026 · Updated 1 time
Summary
This early-phase trial will test the safety and feasibility of adding the experimental drug glofitamab to standard chemoimmunotherapy (R-CHOP) in 15 people newly diagnosed with HIV-associated large B-cell lymphoma. Glofitamab is a bispecific antibody that helps the immune system attack cancer cells. The main goal is to see if at least 12 out of 15 participants can complete four full cycles of treatment without major issues.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH GRADE B-CELL LYMPHOMA, NOT OTHERWISE SPECIFIED are added.
By submitting, you agree to our Terms of use
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
glofitamab plus R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone)
What this could lead to
If this combination proves safe and feasible, it could lead to a new treatment option for people with HIV-associated large B-cell lymphoma, potentially improving outcomes in this underserved population.
What could go wrong
This is a very early phase 1 trial with only 15 participants, so results may not apply to everyone. The combination may cause serious side effects like cytokine release syndrome or infections, and it is not yet known if it works better than standard care.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.